Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Depreciation and Depletion: 2010-2016

Historic Depreciation and Depletion for Lineage Cell Therapeutics (LCTX) over the last 6 years, with Sep 2016 value amounting to $248,000.

  • Lineage Cell Therapeutics' Depreciation and Depletion fell 6.06% to $248,000 in Q3 2016 from the same period last year, while for Sep 2016 it was $1.3 million, marking a year-over-year increase of 25.65%. This contributed to the annual value of $1.1 million for FY2015, which is 2.57% up from last year.
  • Latest data reveals that Lineage Cell Therapeutics reported Depreciation and Depletion of $248,000 as of Q3 2016, which was down 22.26% from $319,000 recorded in Q2 2016.
  • Over the past 5 years, Lineage Cell Therapeutics' Depreciation and Depletion peaked at $429,000 during Q1 2016, and registered a low of $88,692 during Q1 2012.
  • Its 3-year average for Depreciation and Depletion is $284,091, with a median of $264,000 in 2015.
  • Its Depreciation and Depletion has fluctuated over the past 5 years, first skyrocketed by 321.08% in 2013, then slumped by 35.42% in 2014.
  • Lineage Cell Therapeutics' Depreciation and Depletion (Quarterly) stood at $102,820 in 2012, then surged by 130.86% to $237,370 in 2013, then rose by 8.27% to $257,000 in 2014, then increased by 17.51% to $302,000 in 2015, then dropped by 6.06% to $248,000 in 2016.
  • Its last three reported values are $248,000 in Q3 2016, $319,000 for Q2 2016, and $429,000 during Q1 2016.